291 related articles for article (PubMed ID: 15779435)
1. [Therapies for newly-onset diabetic patients].
Kawamori R
Nihon Rinsho; 2005 Feb; 63 Suppl 2():525-32. PubMed ID: 15779435
[No Abstract] [Full Text] [Related]
2. [Postprandial hypoglycemia].
Mori Y
Nihon Rinsho; 2006 Sep; Suppl 3():224-9. PubMed ID: 17022536
[No Abstract] [Full Text] [Related]
3. [Effects of nateglinide in impaired glucose tolerance subjects].
Hirose T
Nihon Rinsho; 2005 Feb; 63 Suppl 2():438-43. PubMed ID: 15779419
[No Abstract] [Full Text] [Related]
4. [Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
Kellerer M; Jakob S; Linn T; Haslbeck M
MMW Fortschr Med; 2003 Dec; 145(51-52):I-X; quiz XI-XII. PubMed ID: 14974337
[No Abstract] [Full Text] [Related]
5. [Preclinical studies of AY4166 (A-4166)].
Kondo N
Nihon Rinsho; 1997 Nov; 55 Suppl():159-63. PubMed ID: 9434461
[No Abstract] [Full Text] [Related]
6. New drugs for diabetes.
Tack CJ; Smits P
Neth J Med; 1999 Nov; 55(5):209-11. PubMed ID: 10593129
[No Abstract] [Full Text] [Related]
7. [Nateglinide].
Notoya Y; Kikuchi M
Nihon Rinsho; 2002 Sep; 60 Suppl 9():371-5. PubMed ID: 12387020
[No Abstract] [Full Text] [Related]
8. Restoring post-prandial insulin release in type 2 diabetes.
Andrews J
Hosp Med; 2002 Feb; 63(2):95-8. PubMed ID: 11902096
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes].
Kitaoka H
Nihon Rinsho; 2002 Sep; 60 Suppl 9():464-9. PubMed ID: 12387035
[No Abstract] [Full Text] [Related]
10. [Adverse effects of oral hypoglycemic agents].
Mori Y; Sekihara H
Nihon Rinsho; 2002 Sep; 60 Suppl 9():325-31. PubMed ID: 12387013
[No Abstract] [Full Text] [Related]
11. A review of nateglinide in the management of patients with type 2 diabetes.
Tentolouris N; Voulgari C; Katsilambros N
Vasc Health Risk Manag; 2007; 3(6):797-807. PubMed ID: 18200800
[TBL] [Abstract][Full Text] [Related]
12. [Nateglinide and mitiglinide].
Odawara M
Nihon Rinsho; 2003 Jul; 61(7):1230-7. PubMed ID: 12877090
[TBL] [Abstract][Full Text] [Related]
13. [A comparison of efficacy and tolerance of nateglinide and acarbose monotherapy in type 2 diabetes mellitus].
Pan CY; Gao Y; Li GW; Zhu XX; Gao X; Liu X
Zhonghua Nei Ke Za Zhi; 2009 Apr; 48(4):304-7. PubMed ID: 19576120
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacological properties of nateglinide, rapid-onset/short-duration insulinotropic agent, in the treatment of type 2 diabetes].
Ikenoue T; Kondo N
Nihon Yakurigaku Zasshi; 2000 Sep; 116(3):171-80. PubMed ID: 11031747
[TBL] [Abstract][Full Text] [Related]
15. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
Campbell IW
Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
[TBL] [Abstract][Full Text] [Related]
16. Post-load hyperglycaemia-an inappropriate therapeutic target.
Yudkin JS
Lancet; 2002 Jan; 359(9301):166-7. PubMed ID: 11809285
[No Abstract] [Full Text] [Related]
17. [Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus].
Yamada K
Nihon Rinsho; 2003 Jul; 61(7):1219-23. PubMed ID: 12877088
[TBL] [Abstract][Full Text] [Related]
18. Advances in oral therapy for type 2 diabetes.
Davis SN
Postgrad Med; 2000 May; 107(6 Suppl Key):16-20. PubMed ID: 19667506
[TBL] [Abstract][Full Text] [Related]
19. [Glinide(s), sulfonylurea(s)].
Arakawa M; Hirose T
Nihon Rinsho; 2006 Nov; 64(11):2107-12. PubMed ID: 17087304
[TBL] [Abstract][Full Text] [Related]
20. [Progress in therapy for diabetes mellitus--insulin-secretion inducing oral hypoglycemic agents].
Nagashima K; Inagaki N
Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):737-41. PubMed ID: 19472523
[No Abstract] [Full Text] [Related]
[Next] [New Search]
